CN106176801A - Hydrogen sulfide purposes in struvite anemia medicine is treated in preparation - Google Patents
Hydrogen sulfide purposes in struvite anemia medicine is treated in preparation Download PDFInfo
- Publication number
- CN106176801A CN106176801A CN201510228271.7A CN201510228271A CN106176801A CN 106176801 A CN106176801 A CN 106176801A CN 201510228271 A CN201510228271 A CN 201510228271A CN 106176801 A CN106176801 A CN 106176801A
- Authority
- CN
- China
- Prior art keywords
- hydrogen sulfide
- lipopolysaccharide
- tfr
- iron
- struvite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to medicine pharmacy field, relate to the hydrogen sulfide new medicinal usage in pharmacy, particularly relate to hydrogen sulfide purposes in struvite anemia medicine is treated in preparation.Having carried out hydrogen sulfide in the present invention to test the impact of normal mouse and struvite AMS ferrum, experimental result shows: under physiological conditions, hydrogen sulfide dramatically increases mice serum ferrum by increasing TFR protein expression and carries ferrum saturation；For struvite anemia mice model, TFR and the FPN protein decreased caused by suppression lipopolysaccharide, significantly inhibit the serum levels of iron that lipopolysaccharide causes and the decline carrying ferrum saturation；For the primary macrophage of abdominal cavity induction, under physiological conditions, hydrogen sulfide significantly increases TFR protein expression, the cell model processed for lipopolysaccharide, the decline of the TFR that hydrogen sulfide suppression lipopolysaccharide causes.Experimental result confirms, hydrogen sulfide can be used for preparation and treats the medicine of struvite anemia.
Description
Technical field
The invention belongs to medicine pharmacy field, relate to the hydrogen sulfide new medicinal usage in pharmacy, particularly relate to hydrogen sulfide purposes in struvite anemia medicine is treated in preparation.
Background technology
Prior art discloses ferrum is the indispensable essential trace element of all life body, is also transition metal the abundantest in human body；Research display, ferrum stable state must be by means of the absorption of iron ion, the coordination absorbing, utilize, store between links, and one link of any of which goes wrong, and all will cause the change of iron content；Iron content is too high or too low all will affect the biologic activity of body；As, iron deficiency can cause the organism metabolic disorder with anemia as main clinic symptoms；Iron deficiency anemia is modal a kind of nutrient deficiency disease in worldwide, especially prominent in developing country；Having statistics display, the sickness rate in China's iron deficiency anemia 2002 is 15%.
Research report, hydrogen sulfide (hydrogen sulfide, H2S) being a kind of important gas molecules, it has become the third biogas signaling molecule (gasotransmitter) after NO and CO；The enzyme that catalysis H2S generates is dispersed throughout each systems such as body circulation, breathing, immunity, neural, digestion and reproduction；Above-mentioned enzyme includes CBS (cystathionine beta-synthase, cystathionine beta-synthase), CSE (cystathionine gamma-lyase, cystathionine γ-lyase；Also name as gamma-cystathionase) and 3-MST (3-mercaptopyruvate sulfurtransferase, 3-Mercaptopyruvate sulfurtransferase)；Described CBS and CSE is primarily present in cytoplasm, and described 3-MST is primarily present in mitochondrion (Predmore et al., 2012)；NaHS (Sodium hydrosulfide, NaSH) is the rapid releasing agent of a kind of conventional hydrogen sulfide, and it is widely used in the research of hydrogen sulfide；As other two kinds of biogas signaling molecule NO and CO above-mentioned, described H2S has the effect of expansion blood vessel and has important function (Paul and Snyder, 2012) in inflammatory reaction.But, up to now, there is not yet about hydrogen sulfide and iron metabolism whether about and the hydrogen sulfide research report to the effect of struvite anemia.
Summary of the invention
It is an object of the invention to provide the hydrogen sulfide new pharmaceutical usage in pharmacy, particularly relate to hydrogen sulfide purposes in struvite anemia medicine is treated in preparation.
In the present invention, carry out hydrogen sulfide and the impact of normal mouse and struvite AMS ferrum has been tested, whether affect the mechanism etc. of serum levels of iron at cell and animal horizontal observational study hydrogen sulfide by affecting iron metabolism albumen；In the present invention, with C57B6 as mouse model, lipopolysaccharide and NaHS is used to intervene, serum levels of iron is detected after 6 and 24 hours, unsaturated iron-binding capacity power, total iron binding capacity and load ferrum saturation, and utilize western blot detection spleen sample to take the photograph ferritin TFR and row's ferritin FPN protein expression level；The primary macrophage simultaneously utilizing abdominal cavity to induce is cell model, intervenes 6 hours and 24 hours with lipopolysaccharide and NaHS, and ferritin TFR and row's ferritin FPN protein expression level are taken the photograph in western blot detection；Experimental result shows: under physiological conditions, and hydrogen sulfide dramatically increases mice serum ferrum by increasing TFR protein expression and carries ferrum saturation；For struvite anemia mice model, TFR and the FPN protein decreased that hydrogen sulfide is caused by suppression lipopolysaccharide, significantly inhibit the serum levels of iron that lipopolysaccharide causes and the decline carrying ferrum saturation；For the primary macrophage of abdominal cavity induction, under physiological conditions, hydrogen sulfide significantly increases TFR protein expression, the cell model processed for lipopolysaccharide, and hydrogen sulfide can suppress the decline of the TFR that lipopolysaccharide causes.
Experimental result of the present invention confirms, described hydrogen sulfide can be used for preparation and treats the medicine of struvite anemia.
In the present invention, it is provided that relevant initialism remarks are described as follows:
CON (control) compares,
NaSH (Sodium hydrosulfide) NaHS,
LPS (Lipopolysaccharide) lipopolysaccharide,
Body Weight body weight,
FPN (Ferroportin) cell membrane iron transporter,
TFR (Transferrin Receptor) TfR,
Serum iron serum levels of iron,
UIBC (unsaturated iron-binding capacity) unsaturated iron-binding capacity,
TIBC (total iron-binding capacity) total iron binding capacity,
TF (%) carries ferrum saturation,
Western blot Western blot (immunoblotting).
Accompanying drawing explanation
Fig. 1 shows under physiological conditions after lumbar injection NaHS, and C57B6 mice serum ferrum increases；Under inflammatory conditions, NaHS can suppress the decline of the serum levels of iron that lipopolysaccharide causes；Wherein, 8 week old C57B6 mices, after adaptability feeds one week, it is randomly divided into 4 groups by body weight, often group 5, CON group disposable celiac injection PBS；NaSH group disposable celiac injection NaHS 5mg/kg Body Weight；LPS group disposable celiac injection lipopolysaccharide 1mg/kg Body Weight；LPS+NaSH group disposable celiac injection NaHS 5mg/kg Body Weight and 1mg/kg Body Weight, plucks eyeball after 6 hours and 24 hours and takes blood；Figure 1A, the content of each experimental group serum levels of iron after injecting 6 hours；Figure 1B, the content of each experimental group serum levels of iron after injecting 24 hours；Fig. 1 C, each experimental group serum unsaturated iron-binding capacity power after injecting 6 hours；Fig. 1 D, serum unsaturated iron-binding capacity power after injecting 24 hours.
Fig. 2 shows under physiological conditions after lumbar injection NaHS, and C57B6 mice serum ferrum increases；Under inflammatory conditions, NaHS can suppress the decline of the serum levels of iron that lipopolysaccharide causes, wherein, 8 week old C57B6 mices, after adaptability feeds one week, is randomly divided into 4 groups by body weight, often group 5；CON group disposable celiac injection PBS；NaSH group disposable celiac injection NaHS 5mg/kg Body Weight；LPS group disposable celiac injection lipopolysaccharide 1mg/kg Body Weight；LPS+NaSH group disposable celiac injection NaHS 5mg/kg Body Weight and 1mg/kg Body Weight, plucks eyeball after 6 hours and 24 hours and takes blood；Fig. 2 A, each experimental group serum total iron binding capacity after injecting 6 hours；Fig. 2 B, each experimental group serum total iron binding capacity after injecting 24 hours；Fig. 2 C, each experimental group serum carrier saturation after injecting 6 hours；Fig. 2 D, each experimental group serum carrier saturation after injecting 24 hours.
Fig. 3 shows under physiological conditions after lumbar injection NaHS, and TFR expressing quantity increases；Under inflammatory conditions, NaHS can suppress the decline of the TFR that lipopolysaccharide causes, wherein, 8 week old C57B6 mices, after adaptability feeds one week, is randomly divided into 4 groups by body weight, often group 5；CON group disposable celiac injection PBS；NaSH group disposable celiac injection NaHS 5mg/kg Body Weight；LPS group disposable celiac injection lipopolysaccharide 1mg/kg Body Weight；LPS+NaSH group disposable celiac injection NaHS 5mg/kg Body Weight and 1mg/kg Body Weight, pluck eyeball after 6 hours and take blood, and take spleen, the content of TFR in Western Blot detection spleen, gray analysis made by Image J software, and GraphPad software is mapped.
Fig. 4 shows under physiological conditions after lumbar injection NaHS, and FPN protein expression is without notable change；Under inflammatory conditions, NaHS can suppress the decline of the FPN that lipopolysaccharide causes；Wherein 8 week old C57B6 mice, after adaptability feeds one week, is randomly divided into 4 groups by body weight, often group 5；CON group disposable celiac injection PBS；NaSH group disposable celiac injection NaHS 5mg/kg Body Weight；LPS group disposable celiac injection lipopolysaccharide 1mg/kg Body Weight；LPS+NaSH group disposable celiac injection NaHS 5mg/kg Body Weight and 1mg/kg Body Weight, pluck eyeball after 6 hours and take blood, and take spleen, the content of FPN in Western Blot detection spleen, gray analysis made by Image J software, and GraphPad software is mapped.
Fig. 5 shows the primary macrophage that C57B6 mouse peritoneal is induced, and under physiological conditions, NaHS increases the expression of TFR albumen；Under inflammatory conditions, the decline of the TFR albumen that NaHS suppression lipopolysaccharide causes；Wherein, the C57B6 mice of 8 week old, after adaptability feeds one week, the thioglycollate medium of the 3% of every mouse peritoneal injection 1ml, collect primary macrophage after three days, according to every hole 2 × 106Individual cell is inoculated in 6 orifice plates, CON group adds PBS, NaSH group gives final concentration 200 μm ol NaHS, LPS group gives the lipopolysaccharide of 1 μ g/ml, LPS+NaSH group gives final concentration 200 μm ol NaHS and the lipopolysaccharide of 1 μ g/ml, collecting cell after 24 hours, Western Blot detects the expression of intracellular TFR albumen.
Detailed description of the invention
Embodiment 1
Material and method:
1. animal C57B6 male mice, 8 week old, after adaptability feeds one week, it is randomly divided into four groups by body weight, it is respectively blank group (CON), NaHS group (NaSH), lipopolysaccharide group (LPS), lipopolysaccharide and NaHS group (LPS+NaSH), often group 5.Mice is administered according to 100 μ l/10g, lumbar injection, blank group gives PBS, NaHS group is according to 5mg/kg Body Weight NaHS, lipopolysaccharide group is according to 1mg/kg Body Weight lipopolysaccharide, and lipopolysaccharide and NaHS group give 5mg/kg Body Weight NaHS and 1mg/kg Body Weight lipopolysaccharide simultaneously.After being administered 6 hours and 24 hours, plucking eyeball and take blood, conventional solution takes spleen；
2. prepare serum:
The blood sample room temperature plucking eyeball acquisition is placed 1 hour, and 4000 leave the heart 5 minutes, take supernatant, again 4000 leave the heart 5 minutes, take supernatant and be serum；
3. serum levels of iron and the detection of unsaturated iron-binding capacity power
The Iron/TIBC Reagent Set kits serum of POINTE, the index of correlation of detection ferrum is used to use:
A, serum levels of iron
Prepare to be marked with blank respectively, 96 orifice plates of standard and sample, every hole adds 100 μ liron buffer, 20 μ l deionized waters are added in blank, the Iron standard (500 μ g/dl) of 20 μ l is added in standard, sample 20 μ l is added in sample, with blank for 0, the absorption reading (A1) in each hole of 560nm is measured by microplate reader, each hole adds the iron color reagent of 2 μ l, mix homogeneously, place 10 minutes for 37 degree, with blank for 0, the absorption reading (A2) in each hole of 560nm is measured by microplate reader；
Serum levels of iron (μ g/dl)=(A2sample-A1sample)/(A2std-A1std) * concentration of St；
B, serum UIBC
Prepare 96 orifice plates of respectively labelling blank, standard and sample, every hole adds the UIBC buffer of 80 μ l, blank adds the deionized water of 40 μ l, standard adds 20 μ l deionized waters and 20 μ l.Standard, the sample and the standard of 20 μ l of 20 μ l is added in sample, with blank for 0, the absorption reading (A1) in each hole of 560nm is measured by microplate reader, every hole adds the iron color reagent of 2 μ l, mix homogeneously, places 10 minutes for 37 degree, with blank for 0, measure the absorption reading (A2) in each hole of 560nm by microplate reader
UIBC (μ g/dl)=Conc of std-(A2sample-A1sample)/(A2std-A1std) * Concentr ation of stdTIBC (μ g/dl)=serum levels of iron+UIBC TF (%)=serum levels of iron/TIBC；
4, prepare histone:
0.01 gram of spleen tissue, adds 100 μ lRIPA lysates, and agitator shakes, and 60 hertz, 3 minutes, 13200 left the heart 15 minutes, take supernatant；
5, the primary macrophage of abdominal cavity induction
C57B6 male mice, 8 week old, after adaptability feeds one week, 3% thioglycollate medium lumbar injection, conventional treatment mice after three days, the alcohol solution dipping of 75% 10 seconds, conventional treatment sterilization abdominal part muscle layer；Inhaling 10mlPBS with 10ml syringe and inject abdominal cavity, after soft abdominal part, draw cell suspension with 5ml syringe, 300g is centrifuged 10 minutes, cell is diluted to 1 × 106/ milliliter, is inoculated into 6 orifice plates, and every hole adds the cell suspension of 2 milliliters, 5%CO2After incubation 3h, change liquid, and with PBS 2 times, discard nonadherent cell, add DMEM height sugar complete medium (10% hyclone, the penicillin of 1% and streptomycin), agent-feeding treatment cell after 24 hours, matched group adds PBS, NaHS group adds the NaHS of 200 μm ol final concentrations, LPS group adds the lipopolysaccharide of 1 μ g/ml final concentration, and NaHS adds lipopolysaccharide group and adds NaHS and the lipopolysaccharide of 1 μ g/ml final concentration of 200 μm ol final concentrations, collects cell behind 6 hours and 24 hours；
6, prepare cell protein sample
Cell takes out to be put on ice immediately, washes three times cells with PBS, and what every hole added 60 μ l has added protease inhibitor cell pyrolysis liquid, scrapes cell, collects the centrifuge tube of 1.5ml, stands 30 minutes on ice, and ultrasonic five times, 13200 leave the heart 15 minutes, sucts clear.
Experimental result shows:
The most in physiological conditions, hydrogen sulfide dramatically increases serum levels of iron and carries ferrum saturation, and in the case of struvite anemia, hydrogen sulfide can significantly suppress serum levels of iron and the decline of carrier saturation；
Wherein, in order to study hydrogen sulfide to serum levels of iron and the effect to lipopolysaccharide-induced struvite anemia, employing SPF level C57B6 mice, 8 week old, adaptability is randomly divided into four groups according to body weight after raising one week, often group 5, once daily, experiment make use of the rapid releasing agent NaHS of hydrogen sulfide.It is carried out at respectively 6 hours and 24 hours and plucks eyeball and take that blood is centrifugal collects serum.Test result indicate that, under physiological conditions, after injecting 6 hours, hydrogen sulfide increases serum levels of iron, but does not has significant difference (Figure 1A), and after injecting 24 hours, can the most significantly increase the content of serum levels of iron, P < O.O1 (Figure 1B)；After injecting 6 hours and after 24 hours, hydrogen sulfide does not has significant impact (Fig. 1 C, 1D) to unsaturated iron-binding capacity power.Under inflammatory conditions, after injecting 6 hours, the decline of the serum levels of iron that lipopolysaccharide is caused by hydrogen sulfide has slight rise effect, but there is no significant difference (Figure 1A), and after injecting 24 hours, hydrogen sulfide can suppress the decline of lipopolysaccharide-induced serum levels of iron, has significant difference, p < 0.05 (Figure 1B)；After injecting 6 hours and 24 hours, lipopolysaccharide-induced unsaturated iron-binding capacity power is raised by hydrogen sulfide does not has the impact (Fig. 1 C, 1D) of significance.In summary, animal injection 5mg/kg NaHS can significantly increase the content of serum levels of iron and improve the struvite anemia that lipopolysaccharide causes.
Meanwhile, the present invention have detected injection 6 hours and 24 hours serum total iron binding capacities, test result indicate that hydrogen sulfide, no matter under physiology or inflammatory conditions, has no significant effect (Fig. 2 A, Fig. 2 B) to serum total iron binding capacity.For carry ferrum saturation, inject 6 hours under physiology and inflammatory conditions hydrogen sulfide on load ferrum saturation the most do not affect (Fig. 2 C)；After injecting 24 hours, under physiological conditions, hydrogen sulfide can dramatically increase load ferrum saturation P, and < 0.05 (Fig. 2 D), under inflammatory conditions, hydrogen sulfide can suppress the decline carrying ferrum saturation that lipopolysaccharide causes, and has pole significant difference (P < 0.0001) (Fig. 2 D).
The most in physiological conditions, hydrogen sulfide dramatically increases mouse spleen TFR and expresses, in the case of struvite anemia,
Hydrogen sulfide can significantly suppress the decline of lipopolysaccharide-induced TFR；Wherein,
Hydrogen sulfide can significantly increase serum levels of iron and carry ferrum saturation, lipopolysaccharide-induced struvite anemia can also be improved simultaneously, further experiment have detected major protein TFR of ferrum picked-up and the protein expression situation of the albumen FPN of ferrum discharge, result shows, under physiological conditions, animal lumbar injection 5mg/kg NaHS, after 6 hours, can the most significantly increase the expression (P < 0.01) of ferrum picked-up albumen TFR.The lipopolysaccharide of animal lumbar injection 1mg/kg is after 6 hours, TFR protein expression is caused to decline (P<0.01), and inject NaHS and lipopolysaccharide simultaneously, NaHS can reverse the decline of TFR, the expression making TFR albumen rises to Normal group TFR protein expression level, does not has significant difference (P>0.05) (Fig. 3) with Normal group.
The most in physiological conditions, hydrogen sulfide does not affects expression to mouse spleen FPN, and in the case of struvite anemia, hydrogen sulfide can significantly suppress the decline of lipopolysaccharide-induced FPN, wherein,
In view of Ferroportin (FPN) is the unique channel protein toward extracellular transport nonheme iron being currently known, it is mainly expressed at macrophage, duodenal epithelium cell and liver parenchymal cell, under physiological condition, ferrum output albumen FPN is not affected by the NaHS of C57B6 mouse peritoneal injection 5mg/kg, the lipopolysaccharide of lumbar injection 1mg/kg can significantly reduce the expression (P < 0.0001) of FPN albumen, injection lipopolysaccharide and NaHS can the most significantly reverse the decline (P < 0.0001) (Fig. 4) of the FPN that lipopolysaccharide causes simultaneously, originally test result indicate that, the lipopolysaccharide-induced FPN protein level that hydrogen sulfide can significantly suppress decline；
This experimental result is further characterized by, and under physiological condition, hydrogen sulfide can significantly increase the level of mice serum, and it is to take the photograph ferritin TFR protein expression level by increase, makes the dramatically increasing of ferrum of entrance serum；Under inflammatory conditions, hydrogen sulfide can improve lipopolysaccharide-induced struvite anemia, and it is the decline of TFR and the FPN protein expression level caused by suppression lipopolysaccharide, so that the ferrum entering serum increases.
nullThe most in physiological conditions，Hydrogen sulfide dramatically increases the expression of the TFR of the macrophage of mouse peritoneal induction，In the case of struvite anemia，Hydrogen sulfide can significantly suppress the decline of lipopolysaccharide-induced TFR，Wherein，Utilize the primary macrophage that thioglycollate medium abdominal cavity is induced，The research hydrogen sulfide single factors impact on iron metabolism albumen，Result shows，The NaHS incubated cell of 200 μm ol can significantly increase the expression (P < 0.01) of TFR after 24 hours，The decline (P < 0.0001) that the lipopolysaccharide adding 1 μ g/ml can significantly make TFR express,And it is simultaneously introduced NaHS and lipopolysaccharide，Then can reverse the decline of the TFR protein expression level that lipopolysaccharide causes，TFR protein expression level and matched group is made not to have significant difference (P > 0.05).
Claims (5)
1. hydrogen sulfide purposes in struvite anemia medicine is treated in preparation.
2. the purposes as described in claim 1, it is characterised in that described hydrogen sulfide in physiological conditions, significantly
Increase serum levels of iron and carry ferrum saturation, in the case of struvite anemia, significantly inhibiting serum levels of iron and carrier
The decline of saturation.
3. the purposes as described in claim 1, it is characterised in that described hydrogen sulfide significantly increases
Add mouse spleen TFR to express, in the case of struvite anemia, significantly inhibit lipopolysaccharide-induced TFR
Decline.
4. the purposes as described in claim 1, it is characterised in that described hydrogen sulfide is in the case of struvite anemia
Significantly inhibit the decline of lipopolysaccharide-induced FPN.
5. the purposes as described in claim 1, it is characterised in that described hydrogen sulfide significantly increases
Adding the expression of the TFR of macrophage, in the case of struvite anemia, significantly suppression is lipopolysaccharide-induced
The decline of TFR.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510228271.7A CN106176801B (en) | 2015-05-06 | 2015-05-06 | Application of hydrogen sulfide in preparation of medicine for treating inflammatory anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510228271.7A CN106176801B (en) | 2015-05-06 | 2015-05-06 | Application of hydrogen sulfide in preparation of medicine for treating inflammatory anemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106176801A true CN106176801A (en) | 2016-12-07 |
| CN106176801B CN106176801B (en) | 2020-06-09 |
Family
ID=57459166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510228271.7A Expired - Fee Related CN106176801B (en) | 2015-05-06 | 2015-05-06 | Application of hydrogen sulfide in preparation of medicine for treating inflammatory anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176801B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107536849A (en) * | 2016-06-26 | 2018-01-05 | 复旦大学 | Hydrogen sulfide is preparing treatment AMPK as the purposes in the inflammatory anaemia medicine of target spot |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403154A (en) * | 2002-10-21 | 2003-03-19 | 钱忠明 | Application of Hepcidin in pharmacy |
| CN101011413A (en) * | 2007-02-06 | 2007-08-08 | 复旦大学 | Use of hydrogen sulfide and its donor sodium hydrosulfide in the production of medicaments |
| WO2008089439A2 (en) * | 2007-01-18 | 2008-07-24 | Fred Hutchinson Cancer Research Center | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
| CN101940785A (en) * | 2010-09-25 | 2011-01-12 | 浙江大学 | Hydrogen sulfide-producing enzyme preparation and use thereof |
| CN102078327A (en) * | 2009-11-27 | 2011-06-01 | 复旦大学 | Application of hydrogen sulfide donor to preparation of medicine for treating central nervous system disease |
| CN102503932A (en) * | 2011-10-26 | 2012-06-20 | 南京师范大学 | Novel gas signal molecule donator and preparation method and use thereof |
| CN103040861A (en) * | 2012-12-07 | 2013-04-17 | 苏州大学 | Application of hydrogen sulfide releasing agent in preparation of medicament for treating renal fibrosis disease |
| CN103622992A (en) * | 2012-08-26 | 2014-03-12 | 复旦大学 | Application of hydrogen sulfide and donor thereof sodium hydrosulfide to preparation of medicament for treating diabetes |
| CN103705537A (en) * | 2012-09-29 | 2014-04-09 | 复旦大学 | Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders |
| CN104109145A (en) * | 2014-06-22 | 2014-10-22 | 徐州医学院 | Flavonoid structure based hydrogen sulfide donor derivative and application in treatment of neuroinflammation related diseases thereof |
| CN104387375A (en) * | 2014-09-24 | 2015-03-04 | 中国药科大学 | Hydrogen sulfide donor type isochromanone derivatives, preparation method and uses thereof |
| CN104825473A (en) * | 2015-05-04 | 2015-08-12 | 中国人民解放军第三军医大学第一附属医院 | Applications of aspirin in preparation of brain iron metabolism deposition treating drugs |
-
2015
- 2015-05-06 CN CN201510228271.7A patent/CN106176801B/en not_active Expired - Fee Related
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403154A (en) * | 2002-10-21 | 2003-03-19 | 钱忠明 | Application of Hepcidin in pharmacy |
| WO2008089439A2 (en) * | 2007-01-18 | 2008-07-24 | Fred Hutchinson Cancer Research Center | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
| CN101011413A (en) * | 2007-02-06 | 2007-08-08 | 复旦大学 | Use of hydrogen sulfide and its donor sodium hydrosulfide in the production of medicaments |
| CN102078327A (en) * | 2009-11-27 | 2011-06-01 | 复旦大学 | Application of hydrogen sulfide donor to preparation of medicine for treating central nervous system disease |
| CN102078327B (en) * | 2009-11-27 | 2014-01-08 | 复旦大学 | Application of hydrogen sulfide donor to preparation of medicine for treating central nervous system disease |
| CN101940785A (en) * | 2010-09-25 | 2011-01-12 | 浙江大学 | Hydrogen sulfide-producing enzyme preparation and use thereof |
| CN102503932A (en) * | 2011-10-26 | 2012-06-20 | 南京师范大学 | Novel gas signal molecule donator and preparation method and use thereof |
| CN103622992A (en) * | 2012-08-26 | 2014-03-12 | 复旦大学 | Application of hydrogen sulfide and donor thereof sodium hydrosulfide to preparation of medicament for treating diabetes |
| CN103705537A (en) * | 2012-09-29 | 2014-04-09 | 复旦大学 | Applications of hydrogen sulfide and donor thereof sodium hydrosulfide in preparation of medicines used for treating lipid metabolism disorders |
| CN103040861A (en) * | 2012-12-07 | 2013-04-17 | 苏州大学 | Application of hydrogen sulfide releasing agent in preparation of medicament for treating renal fibrosis disease |
| CN104109145A (en) * | 2014-06-22 | 2014-10-22 | 徐州医学院 | Flavonoid structure based hydrogen sulfide donor derivative and application in treatment of neuroinflammation related diseases thereof |
| CN104387375A (en) * | 2014-09-24 | 2015-03-04 | 中国药科大学 | Hydrogen sulfide donor type isochromanone derivatives, preparation method and uses thereof |
| CN104825473A (en) * | 2015-05-04 | 2015-08-12 | 中国人民解放军第三军医大学第一附属医院 | Applications of aspirin in preparation of brain iron metabolism deposition treating drugs |
Non-Patent Citations (4)
| Title |
|---|
| HONG XIN等: "Hydrogen Sulfide Attenuates Inflammatory Hepcidin by Reducing IL-6 Secretion and Promoting SIRT1-Mediated STAT3 Deacetylation", 《ANTIOXIDANTS & REDOX SIGNALING》 * |
| MINJUN WANG等: "S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammationby InhibitingIL-6/STAT3 Pathway", 《PLOS ONE》 * |
| 孟祥艳等: "气体信号分子硫化氢在脂多糖诱导大鼠肺急性炎症反应中的作用", 《河北医科大学学报》 * |
| 郁知非: "《临床血液学最近进展》", 31 May 1993, 暨南大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107536849A (en) * | 2016-06-26 | 2018-01-05 | 复旦大学 | Hydrogen sulfide is preparing treatment AMPK as the purposes in the inflammatory anaemia medicine of target spot |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106176801B (en) | 2020-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hatch et al. | A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion | |
| Geerlofs et al. | Repeated dose (90 days) oral toxicity study of ursolic acid in Han-Wistar rats | |
| CN101961345B (en) | Medicinal composition having anti-fatigue function | |
| Zhou et al. | Lactate-driven macrophage polarization in the inflammatory microenvironment alleviates intestinal inflammation | |
| CN106176801A (en) | Hydrogen sulfide purposes in struvite anemia medicine is treated in preparation | |
| CN102260728B (en) | Royal jelly polypeptide and application thereof | |
| Chapman | The role of the colonic flora in maintaining a healthy large bowel mucosa. | |
| CN106491659A (en) | A kind of anti-enteritis spirulina selenizing phycobniliprotein complex of polypeptides and its preparation and application | |
| Chethan et al. | Antioxidant supplementation during treatment of outpatient dogs with parvovirus enteritis ameliorates oxidative stress and attenuates intestinal injury: A randomized controlled trial | |
| CN104000813A (en) | Preventive and therapeutic effect of quercetin to diabetic cataract | |
| Babov et al. | Assessment of biological activity of natural iron-containing mineral waters at their internal application | |
| CN113975329A (en) | Application of Withania somnifera extract in preparation of product for promoting proliferation of beneficial intestinal bacteria | |
| CN102251004B (en) | Preparation method of royal jelly polypeptide | |
| CN106138085A (en) | A kind of have medicine or the health food increasing bone density effect | |
| CN105341938B (en) | The health food of rate of respiratory infection after a kind of reduction strenuous exercise | |
| Zhu et al. | The Efficacy of Adipose-Derived Stem Cells (ADSCs) on Chronic Kidney Disease in Dogs | |
| McCoy et al. | The Adult Dysphagia Pocket Guide: Neuroanatomy to Clinical Practice | |
| Kee | Investigating the role of oxygen gradient in cell development and intrinsic innate immune response in the human gut using microfluidics system | |
| CN106822169A (en) | Application of the cordycepin in the medicine for preparing prevention and/or radiotherapy damage and preparing tumor radiotherapy enhanced sensitivity | |
| CN101857893B (en) | Method and kit for synchronously cultivating bacterium group | |
| Zikavska et al. | Extremely high concentration of folates in premature newborns | |
| Zhang et al. | Study of the effects of Schisandra chinensis (Turcz.) baill polysaccharides on anti-fatigue and anti-hypoxia in mice | |
| Żarczyńska et al. | Disturbances in the acid-base and electrolyte balance and changes in serum mineral concentrations in calves diagnosed with nutritional muscular dystrophy. | |
| VASILYEVNAMORYAKINA | THE STATE OF STUDENTS'BLOOD UNDER CONDITIONS OF MOUNTAIN HYPOXIA. | |
| Martens | Measurement of in vivo and in vitro oxygen levels in the cerebrospinal fluid compartment during infection with Streptococcus suis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200609 |